Licensing and partering opportunities emerging from Japan

Thursday 9 September 2010

The Royal Society, London, United Kingdom

Despite its position as one of the world leaders of cutting edge science and biotechnology, Japan remains one of the most difficult countries for the Western licensing and investment communities to transact with. Following the successful running of the first Japan Biotech Forum last year, transB brings to this unique forum a number of innovative Japanese companies developing preclinical and clinical stage products with real licensing and investment opportunities.

Download conference brochure

Please click here to open the conference brochure (PDF file).

Please click here to open the delegate list (PDF file).

Invited speakers from Japan

transB is bringing a handful of innovative Japanese biotech companies to present at this Forum. Products and technologies listed here are a partial list from their portfolio and more products may be presented.

Japan Bioindustry Association

Mr Setsuo Morishita, Deputy Director, Strategic Planning

Introduction: Overview of the current Japanese biotech industry and outlook

Apposite Capital and Dainippon Sumitomo Pharma Europe

Dr Noriyuki Matsuo, Manager, Research Alliance

Insight into investment strategies adopted by a Japanese pharma company

CanBas (MOTHERS index: 4575)

Clinical stage biopharmaceutical company

Dr Takumi Kawabe, President and CEO

CBP501: Peptide therapeutic for cancer; Phase II (malignant pleural mesothelioma and non-small-cell lung cancer)

CBS9106: Oral small molecule therapeutic for cancer; Preclinical

LivTech

Biotech company developing anti-cancer therapeutic antibodies based on tissue stem cells

Dr Koji Nakamura, CEO

LIV-2008: Monoclonal antibody for pancreatic cancer; Preclinical

REGiMMUNE

Biotech company developing immune-regulating therapeutics

Mr Haru Morita, President and CEO

RGI-2001: Novel therapeutic for graft versus host disease (GvHD); Preclinical

RGI-1001: Novel therapeutic for cedar allergy; Preclinical

RGI-3010: Immune-tolerance inducing liposome encapsulating proinsulin for type I diabetes; Preclinical

Chiome Bioscience

Biotech company with proprietary technology in monoclonal antibodies

Mr Masa Fujiwara,  CEO

ADLib® system: Proprietary technology for fast generation of monoclonal antibodies against tough antigens

D. Western Therapeutics Institute (JASDAQ NEO index: 4576)

Clinical stage biopharmaceutical company with protein kinase inhibitors originated from its proprietary chemical library 

Mr Yuichi Hidaka, President & CEO

Glaucoma project; NCE small molecule for glaucoma; preclinical

Cancer project: Anti-cancer agent with novel MoA; Phase I completed in US

Various NCEs for anti-cancer, anti-thrombotic; Preclinical

Red Abbey Venture Partners

Ms Tomomi Okamoto, Advisor

Luncheon seminar: Current and future investment outlook

ITOCHU Corporation

Mr Koji Abe, General Manager

Luncheon seminar: Current and future investment outlook; Itochu's strategy

Please note: this list of speakers is subject to change, and other companies may be invited to speak. 

Benefits of attending

• Presentations from senior representatives from Japanese biotech companies
• Corporate and product analyses provided as handouts
• One-to-one partnering opportunity
• Networking with delegates from the licensing and investment communities
  

Registration

Standard delegate rate:  £250 + VAT

Additional delegate(s) from the same company:  £200 + VAT

 

Japan Biotech Forum: London 2009

 

Please click here to open the conference brochure from last year (PDF file).

Please click here to open last year's attendee list (PDF file).

Please click on the image below to access video coverage of the forum last year (you will be directed to PharmaTV's website).